Blame a slump in gene therapy stocks in the second half of the year for the relative underperformance of the biotech sector, according to a new analysis.

A proprietary index of 64 drug makers developing gene therapies has “massively underperformed” the broader market since August, Evercore ISI analysts Ravi Mehrotra and Josh Schimmer said in a research note sent to clients on Sunday. By the numbers, Evercore’s gene therapy index is down 22% from August. In the first half of the year, the same collection of gene therapy stocks were up 37%.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy